Current research into retatrutide, a dual activator for GLP-1 and GIP receptors, are demonstrating significant results in addressing obesity and diabetes 2 disease. Initial information suggest a distinct mechanism https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/